Consensus Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Market Closed - Nasdaq Copenhagen 16:20:00 25/06/2024 BST 5-day change 1st Jan Change
1,028 DKK +4.01% Intraday chart for Novo Nordisk A/S +4.77% +47.26%

Evolution of the average Target Price on Novo Nordisk A/S

Price target over the last 5 years

History of analyst recommendation changes

d95f291a2a3329.Le_KJJQiPS-f2-WIHTg6Z9h1z3HeCnUqWnZFdGFkHVc.FK6HcNBTX1rzqbD-Sl9KIKgd_RS2UkFAMQB9OyIyLQcAuYBV43UEdtT2qA~c32d24ab0c1a6bc5cca8bd469ed09a43
NOVO NORDISK : Deutsche Bank remains its Buy rating ZD
NOVO NORDISK : Jefferies reiterates its Sell rating ZD
NOVO NORDISK : Gets a Buy rating from JP Morgan ZD
India's Biocon seeks partner to test generic Wegovy, Ozempic in China RE
NOVO NORDISK : Deutsche Bank remains its Buy rating ZD
NOVO NORDISK : Deutsche Bank reiterates its Buy rating ZD
Sector Update: Health Care MT
Senate Committee to Vote June 18 to Subpoena Novo Nordisk President Doug Langa MT
Argus Research Raises Novo Nordisk Price Target to $160 From $125, Maintains Buy Rating MT
NOVO NORDISK : Buy rating by Goldman Sachs ZD
NOVO NORDISK : Deutsche Bank reaffirms its Buy rating ZD
NOVO NORDISK : JP Morgan reiterates its Buy rating ZD
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline MT
NOVO NORDISK : UBS sticks Neutral ZD
NOVO NORDISK : JP Morgan reaffirms its Buy rating ZD
NOVO NORDISK : UBS reaffirms its Neutral rating ZD
Stifel Lifts Novo Nordisk PT, Keeps Buy Recommendation MT
NOVO NORDISK : Stifel raises its target price CF
Novo Nordisk Reportedly Asked by US Senator to Reduce Prices of Ozempic, Wegovy Drugs in US MT
Novo Nordisk Plans First Bond Sale in 2 Years MT
NOVO NORDISK : Berenberg reiterates its Neutral rating ZD
Novo Nordisk Seeks More Time to Address US Sen. Bernie Sanders' Questions on Drug Pricing MT
NOVO NORDISK : Barclays remains its Buy rating ZD
NOVO NORDISK : UBS sticks Neutral ZD
Novo Nordisk: share price falls, analyst adjusts target CF
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4 DKK
Average target price
938.1 DKK
Spread / Average Target
-5.09%
High Price Target
1,200 DKK
Spread / Highest target
+21.41%
Low Price Target
530 DKK
Spread / Lowest Target
-46.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novo Nordisk A/S

DEUTSCHE BANK RESEARCH Emmanuel Papadakis
JEFFERIES Peter Welford
JPMORGAN Richard Vosser
Argus
GOLDMAN SACHS James Quigley
Stifel Nicolaus
UBS Jo Walton
BERENBERG Kerry Holford
DZ BANK Elmar Kraus
BARCLAYS Emily Field
alphavalue Abhishek Raval
BERNSTEIN RESEARCH Florent Cespedes
BMO Capital
Cantor Fitzgerald
TD Cowen
ODDO BHF
Berenberg Bank
CREDIT SUISSE Lorenzo Biasio
Morgan Stanley
BNP Paribas Exane
JPMorgan Chase
Guggenheim
Bryan, Garnier & Co.
Deutsche Bank Securities
DEUTSCHE BANK Emmanuel Papadakis
Liberum Capital
KEPLER CHEUVREUX David Evans
HSBC Stephen McGarry
INDEPENDENT RESEARCH Tobias Gottschalt
BANK OF AMERICA (BOFA) Sachin Jain
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Consensus Novo Nordisk A/S